3-Chloro-2-ethylbenzonitrile

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3-Chloro-2-ethylbenzonitrile
• 英文别名: 3-chloro-2-ethylbenzonitrile
• 化学式: C₉H₈ClN
• 分子量: 165.62
• InChiKey: RGSGNNZYPIOQFD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  23.8
• 氢给体数：
  0
• 氢受体数：
  1

文献信息

• DIFLUOROMETHYLENE COMPOUND
  申请人：SATO PHARMACEUTICAL CO., LTD.

  公开号：US20150191463A1

  公开（公告）日：2015-07-09

  The present invention relates to a compound having an URAT1 inhibitory activity, and to an URAT1 inhibitor, a blood uric acid level-reducing agent and a pharmaceutical composition containing the compound. More specifically, the present invention relates to a compound represented by the formula (I): wherein R 1 is -Q 1 -A 1 or the like; R 2 is a hydrogen atom, a halogen atom, a lower alkyl group or the like; W 1 , W 2 , W 3 and W 4 are each independently a nitrogen atom or a methine group optionally having substituents, or the like; X and Y are each a single bond, an oxygen atom or the like; Z is a hydroxyl group or COOR 3 or the like.

  本发明涉及一种具有URAT1抑制活性的化合物，以及一种URAT1抑制剂、降低血尿酸水平的药物和含有该化合物的制剂。更具体地，本发明涉及一种由公式（I）表示的化合物： 其中，R1是-Q1-A1或类似物；R2是氢原子、卤原子、低碳基或类似物；W1、W2、W3和W4各自独立地是氮原子或可选取代基的甲烷基，或类似物；X和Y是单键、氧原子或类似物；Z是羟基、COOR3或类似物。
• RING-FUSED COMPOUND
  申请人：SATO PHARMACEUTICAL CO., LTD.

  公开号：US20150203490A1

  公开（公告）日：2015-07-23

  The present invention relates to a compound that has URAT1 inhibitory action, and a URAT1 inhibitor, a blood uric acid level-reducing agent and a pharmaceutical composition comprising the compound. More specifically, the present invention relates to a compound represented by Formula (I) below. [in the formula, R 1 is -Q 1 -A 1 and the like; is a double bond or a single bond; when is a double bond, W 1 is a nitrogen atom or a group represented by the general formula: ═C(R a )—, and W 2 is a nitrogen atom or a group represented by the general formula: ═C(R b )—; when is a single bond, W 1 is a group represented by the general formula: —C(R aa )(R ab )— or a group represented by the general formula: —(C═O)—, and W 2 is a group represented by the general formula: —C(R ba )(R bb )—, a group represented by the general formula: —(C═O)— or a group represented by the general formula: —N(R bc )—; W 3 , W 4 and W 5 are each independently a nitrogen atom or a methine group and the like that may have a substituent; X is a single bond, an oxygen atom and the like; Y is a single bond or (CR Yi R Yi′ ) n ; and Z is a hydroxyl group or COOR 2 and the like.

  本发明涉及一种具有URAT1抑制作用的化合物，以及一种URAT1抑制剂、降低血尿酸水平的药物和包含该化合物的制剂。更具体地说，本发明涉及以下式（I）所表示的化合物。[在该式中，R1为-Q1-A1等；为双键或单键；当为双键时，W1为氮原子或由一般式表示的基团：═C（RA）—，W2为氮原子或由一般式表示的基团：═C（Rb）—；当为单键时，W1为由一般式表示的基团：—C（RAa）（RAb）—或由一般式表示的基团：—（C═O）—，W2为由一般式表示的基团：—C（Rba）（Rbb）—、由一般式表示的基团：—（C═O）—或由一般式表示的基团：—N（Rbc）—；W3、W4和W5各自独立地为氮原子或可能具有取代基的甲烷基等；X为单键、氧原子等；Y为单键或（CRYiRYi′）n；Z为羟基或COOR2等。
• PROCESS FOR PREPARING DIFLUOROMETHYLENE COMPOUNDS
  申请人：Sato Pharmaceutical Co., Ltd.

  公开号：EP3444238A2

  公开（公告）日：2019-02-20

  The invention refers to a method for producing a compound of the formula (1-6):

  本发明涉及一种生产式（1-6）化合物的方法：
• PYRIDONE COMPOUND, AND AGRICULTURAL AND HORTICULTURAL FUNGICIDE HAVING THIS AS ACTIVE COMPONENT
  申请人：Mitsui Chemicals Agro, Inc.

  公开号：EP3611165A1

  公开（公告）日：2020-02-19

  This is to provide a novel compound capable of treating or preventing plant diseases. The pyridone compounds of the present invention are novel compounds and can treat or prevent plant diseases.

  这是为了提供一种能够治疗或预防植物病害的新型化合物。 本发明的吡啶酮化合物属于新型化合物，可以治疗或预防植物病害。
• SELECTIVE INHIBITORS OF NLRP3 INFLAMMASOME
  申请人：Nodthera Limited

  公开号：US20210087147A1

  公开（公告）日：2021-03-25

  The present disclosure relates to compounds of Formula (I): and to their pharmaceutically acceptable salts, pharmaceutical compositions, methods of use, and methods for their preparation. The compounds disclosed herein are useful for inhibiting the maturation of cytokines of the IL-1 family by inhibiting inflammasomes and may be used in the treatment of disorders in which inflammasome activity is implicated, such as autoinflammatory and autoimmune diseases and cancers.